Cargando…
An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
Background: There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S (Vaxzevria, AstraZeneca). Methods: 197 healthcare...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432244/ https://www.ncbi.nlm.nih.gov/pubmed/34501264 http://dx.doi.org/10.3390/jcm10173817 |
_version_ | 1783751120210886656 |
---|---|
author | Vallée, Alexandre Vasse, Marc Mazaux, Laurence Bonan, Brigitte Amiel, Carline Zia-Chahabi, Sara Chan-Hew-Wai, Aurélie Farfour, Eric Camps, Eve Touche, Pauline Barret, Flavie Parquin, François Zucman, David Fourn, Erwan |
author_facet | Vallée, Alexandre Vasse, Marc Mazaux, Laurence Bonan, Brigitte Amiel, Carline Zia-Chahabi, Sara Chan-Hew-Wai, Aurélie Farfour, Eric Camps, Eve Touche, Pauline Barret, Flavie Parquin, François Zucman, David Fourn, Erwan |
author_sort | Vallée, Alexandre |
collection | PubMed |
description | Background: There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S (Vaxzevria, AstraZeneca). Methods: 197 healthcare workers were included in a monocentric observational study in Foch hospital, France, between June and July 2021. The main outcome was the immunogenicity measured by serum SARS-CoV-2 IgG antibodies. Results: 130 participants received the ChAdOx1-S/BNT vaccine and 67 received the BNT/BNT vaccine. The geometric mean of IgG antibodies was significantly higher in the BNT/BNT vaccine group compared to the ChAdOx1-S/BNT vaccine group, namely 10,734.9, 95% CI (9141.1–12,589.3) vs. 7268.6, 95% CI (6501.3–8128.3), respectively (p < 0.001). However, after adjustment for time duration between the prime and second vaccinations, no significant difference was observed (p = 0.181). A negative correlation between antibody levels and time duration between second dose and serology test was observed for the BNT/BNT vaccine (p < 0.001), which remained significant after adjustment for all covariates (p < 0.001), but not for the ChAdOx1-S/BNT vaccine (p = 0.467). Conclusions: Heterologous and homologous schedules of ChAdOx1-S and BNT vaccines present robust immune responses after the second vaccination. The results observed were equivalent after adjustment for covariates and emphasize the importance of flexibility in deploying mRNA and viral vectored vaccines. Nevertheless, applying the ChAdOx1-S schedule vaccination for the heterologous second dose of BNT was associated with decreased IgG antibody levels compared to the homologous BNT/BNT vaccination. |
format | Online Article Text |
id | pubmed-8432244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84322442021-09-11 An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines Vallée, Alexandre Vasse, Marc Mazaux, Laurence Bonan, Brigitte Amiel, Carline Zia-Chahabi, Sara Chan-Hew-Wai, Aurélie Farfour, Eric Camps, Eve Touche, Pauline Barret, Flavie Parquin, François Zucman, David Fourn, Erwan J Clin Med Article Background: There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S (Vaxzevria, AstraZeneca). Methods: 197 healthcare workers were included in a monocentric observational study in Foch hospital, France, between June and July 2021. The main outcome was the immunogenicity measured by serum SARS-CoV-2 IgG antibodies. Results: 130 participants received the ChAdOx1-S/BNT vaccine and 67 received the BNT/BNT vaccine. The geometric mean of IgG antibodies was significantly higher in the BNT/BNT vaccine group compared to the ChAdOx1-S/BNT vaccine group, namely 10,734.9, 95% CI (9141.1–12,589.3) vs. 7268.6, 95% CI (6501.3–8128.3), respectively (p < 0.001). However, after adjustment for time duration between the prime and second vaccinations, no significant difference was observed (p = 0.181). A negative correlation between antibody levels and time duration between second dose and serology test was observed for the BNT/BNT vaccine (p < 0.001), which remained significant after adjustment for all covariates (p < 0.001), but not for the ChAdOx1-S/BNT vaccine (p = 0.467). Conclusions: Heterologous and homologous schedules of ChAdOx1-S and BNT vaccines present robust immune responses after the second vaccination. The results observed were equivalent after adjustment for covariates and emphasize the importance of flexibility in deploying mRNA and viral vectored vaccines. Nevertheless, applying the ChAdOx1-S schedule vaccination for the heterologous second dose of BNT was associated with decreased IgG antibody levels compared to the homologous BNT/BNT vaccination. MDPI 2021-08-25 /pmc/articles/PMC8432244/ /pubmed/34501264 http://dx.doi.org/10.3390/jcm10173817 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vallée, Alexandre Vasse, Marc Mazaux, Laurence Bonan, Brigitte Amiel, Carline Zia-Chahabi, Sara Chan-Hew-Wai, Aurélie Farfour, Eric Camps, Eve Touche, Pauline Barret, Flavie Parquin, François Zucman, David Fourn, Erwan An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines |
title | An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines |
title_full | An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines |
title_fullStr | An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines |
title_full_unstemmed | An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines |
title_short | An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines |
title_sort | immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with chadox1-s and bnt162b2 vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432244/ https://www.ncbi.nlm.nih.gov/pubmed/34501264 http://dx.doi.org/10.3390/jcm10173817 |
work_keys_str_mv | AT valleealexandre animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT vassemarc animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT mazauxlaurence animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT bonanbrigitte animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT amielcarline animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT ziachahabisara animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT chanhewwaiaurelie animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT farfoureric animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT campseve animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT touchepauline animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT barretflavie animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT parquinfrancois animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT zucmandavid animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT fournerwan animmunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT valleealexandre immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT vassemarc immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT mazauxlaurence immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT bonanbrigitte immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT amielcarline immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT ziachahabisara immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT chanhewwaiaurelie immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT farfoureric immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT campseve immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT touchepauline immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT barretflavie immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT parquinfrancois immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT zucmandavid immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines AT fournerwan immunogenicityreportforthecomparisonbetweenheterologousandhomologousprimeboostscheduleswithchadox1sandbnt162b2vaccines |